AI生物科学初创公司Bioptimus获3500万美元种子轮融资
法国人工智能初创公司Bioptimus宣布获得3500万美元种子轮融资，用于构建生物技术的语言模型。
本轮融资由法国生命科学风投公司Sofinnova Partners和公共银行Bpifrance Large Ventures领投。法国风险投资公司Frst和Cathay Innovation、美国投资者Headline、Owkin和亿万富翁企业家Xavier Niel也参与了本轮融资。
Bioptimus成立于2023年，旨在为生物技术领域创建一个大型语言模型。该模型将能够处理生物医学数据，例如科学文献、基因组序列和临床试验结果。
Bioptimus首席执行官兼联合创始人Pierre-Antoine Gourraud表示：“我们正在构建生物技术的语言模型，以帮助科学家和研究人员加速药物发现和开发。”
该公司的语言模型将使用自然语言处理技术来理解和生成生物医学文本。这将使科学家能够更有效地搜索信息、识别模式并生成新的假设。
Bioptimus计划使用这笔资金来扩大其团队、开发其语言模型并与制药和生物技术公司建立合作伙伴关系。
Sofinnova Partners合伙人Antoine Papiernik表示：“Bioptimus正在解决生物技术领域的一个重大挑战。我们相信，他们的语言模型将对药物发现和开发产生变革性影响。”
Bpifrance Large Ventures投资总监Jean-Luc Boulnois补充道：“Bioptimus的团队拥有在人工智能和生物技术领域丰富的经验。我们很高兴支持他们实现这一愿景。”
英语如下：
**Headline: AI Powers Biotech: Bioptimus Raises $35M SeedRound**
**Keywords: AI Biological Models, Seed Funding, Life Sciences**
**Body:**
AI biotech startup Bioptimus has raised $35million in seed funding to build a language model for biology.
The round was led by French life sciences venture capital firm Sofinnova Partners and public bank Bpifrance Large Ventures. French venture capital firms Frst and Cathay Innovation, U.S.-based investors Headline, Owkin, and billionaire entrepreneur Xavier Niel alsoparticipated in the round.
Founded in 2023, Bioptimus aims to create a large language model for the biotechnology sector. The model will be able to process biomedical data, such as scientific literature, genomic sequences, and clinical trial results.
“We are building a language model for biology to help scientists and researchers accelerate drug discovery and development,” said Pierre-Antoine Gourraud, CEO and co-founder of Bioptimus.
The company’s language model will use natural language processing techniques to understand and generate biomedical text. This will enable scientists to search for information, identify patterns, and generate new hypotheses more efficiently.
Bioptimus plans to use the funding to expand its team, develop its language model, and establish partnerships with pharmaceutical and biotech companies.
“Bioptimus is addressing a major challenge in the biotechnology sector,” said Antoine Papiernik, partner at Sofinnova Partners. “We believe their language model will have a transformative impact on drug discovery and development.”
Jean-Luc Boulnois, investment director at Bpifrance Large Ventures, added: “The Bioptimus team has extensive experience in both AI and biotechnology. We are delighted to support them in realizing their vision.”
【来源】https://sifted.eu/articles/bioptimus-owkin-35m-seed
Views: 1